Why LVAD use is stagnant: A failure of diffusion and a path forward

Mandeep Mehra (), Marie Coris and Robin Pointet
Additional contact information
Mandeep Mehra: Brigham and Women's Hospital [Boston]
Marie Coris: BSE - Bordeaux sciences économiques - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique - INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement
Robin Pointet: BSE - Bordeaux sciences économiques - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique - INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement

Post-Print from HAL

Abstract: Background Contemporary left ventricular assist devices (LVADs) provide durable survival and quality-of-life benefits in advanced heart failure (HF). Yet utilization remains strikingly low relative to disease burden. This paradox cannot be explained by technological immaturity or lack of evidence alone. Approach We conducted an integrative conceptual analysis combining contemporary clinical evidence (Clinical Trials, INTERMACS, EUROMACS, transplant policy data) with established frameworks from diffusion-of-innovation theory, learning economics, and health-system organization. The objective was to identify structural mechanisms underlying persistent under-adoption and to offer possible solutions. Findings LVAD stagnation reflects a failure of diffusion rather than innovation alone. Three reinforcing barriers dominate: (1) a persuasion gap driven by delayed referral, absence of simple triggers, and persistent risk aversion; (2) uneven diffusion of cumulative learning due to low and concentrated procedural volumes; and (3) industrial, reimbursement, and policy misalignment that discourages program growth. The result is a self-reinforcing equilibrium in which LVADs remain framed as a last-resort therapy with patients in need who are neither evaluated nor offered LVAD therapy. Interpretation Underuse of LVADs represents a system-level public-health failure and not merely a technological innovation gap. Overcoming it requires structural reform, including standardized referral triggers, regionalized centers-of-excellence, volume-based accreditation, dynamic reimbursement models, and renewed patient-industry-clinician engagement.

Keywords: LVAD; Mechanical circulatory support; Diffusion of innovation; Advanced heart failure; Health policy (search for similar items in EconPapers)
Date: 2026-04
References: Add references at CitEc
Citations:

Published in The Journal of Heart and Lung Transplantation, inPress, ⟨10.1016/j.healun.2026.02.1684⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-05586006

DOI: 10.1016/j.healun.2026.02.1684

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().